State Key Laboratory of Natural Medicines, Center of Advanced Pharmaceuticals and Biomaterials, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, PR China.
School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR China.
J Control Release. 2022 Sep;349:940-953. doi: 10.1016/j.jconrel.2022.07.021. Epub 2022 Aug 9.
Atherosclerotic cardiovascular diseases remain the leading causes of morbidity and mortality worldwide. Cholesterol crystals in atherosclerotic plaques play an essential role in atherosclerosis progression. However, no clinical drugs have been used for removing cholesterol crystals from plaque to counter atherosclerosis. Previous studies identified the hydrophobic domain of lipid bilayer in liposomes acted as sinks for solubilizing hydrophobic cholesterol. Moreover, adjusting the composition of the lipid bilayer in liposomes can enhance its hydrophobic molecule loading capacity. Therefore, in this study, ginsenosides Rb1 (Rb1), one of main active components of ginseng which has a similar structure to cholesterol, is anchored into soy phospholipids bilayer with its hydrophobic region to prepare nano-sponge-like liposomes (Rb1-LPs), aiming to amplify the solubilization of cholesterol in lipid bilayer. For targeting delivery to atherosclerotic plaques, Annexin V (AnxV), a protein that can specifically recognize phosphatidylserine upregulated in atherosclerotic plaques, is applied to decorate the surface of Rb1-LPs by click reaction to obtain the final preparation of AnxV-Rb1-LPs. The in vitro studies showed that incorporating Rb1 into lipid bilayer remarkably increased the affinity of the lipid bilayer to free cholesterol and the solubilization of cholesterol crystals. Additionally, nano-sponge-like liposomes could efficiently reduce the accumulation of cholesterol crystals and improve cholesterol efflux, finally inhibiting inflammation and apoptosis in cholesterol-laden cells. Furthermore, AnxV-Rb1-LPs could efficiently accumulate in atherosclerotic plaques after intravenous injection, exert nano-sponge-like functions to remove intra- and extracellular cholesterol crystals, ultimately alleviating inflammation and apoptosis in atherosclerotic plaques for antiatherosclerosis. Therefore, AnxV-Rb1-LPs provide a potential strategy for removing cholesterol crystals in atherosclerotic plaques and can be further utilized in other diseases with excessive cholesterol accumulation.
动脉粥样硬化性心血管疾病仍然是全球发病率和死亡率的主要原因。动脉粥样硬化斑块中的胆固醇晶体在动脉粥样硬化进展中起着至关重要的作用。然而,目前尚无临床药物可用于从斑块中去除胆固醇晶体以对抗动脉粥样硬化。先前的研究表明,脂质体双层的疏水区可作为溶解疏水性胆固醇的陷井。此外,调整脂质体双层的组成可以增强其疏水分子的载量。因此,在这项研究中,人参的主要活性成分之一人参皂苷 Rb1(Rb1),其结构与胆固醇相似,通过疏水区域锚定到大豆磷脂双层中,制备纳米海绵样脂质体(Rb1-LPs),旨在放大胆固醇在脂质双层中的溶解。为了靶向递送至动脉粥样硬化斑块,Annexin V(AnxV),一种可以特异性识别动脉粥样硬化斑块中上调的磷脂酰丝氨酸的蛋白质,通过点击反应应用于修饰 Rb1-LPs 的表面,以获得最终的 Annexin V-Rb1-LPs 制备物。体外研究表明,将 Rb1 掺入脂质双层中显著增加了脂质双层对游离胆固醇的亲和力和胆固醇晶体的溶解。此外,纳米海绵样脂质体可以有效地减少胆固醇晶体的积累并促进胆固醇外排,最终抑制载脂蛋白细胞中的炎症和细胞凋亡。此外,静脉注射后,AnxV-Rb1-LPs 可以有效地在动脉粥样硬化斑块中积累,发挥纳米海绵样功能以去除内外源胆固醇晶体,最终减轻动脉粥样硬化斑块中的炎症和细胞凋亡,从而发挥抗动脉粥样硬化作用。因此,AnxV-Rb1-LPs 为去除动脉粥样硬化斑块中的胆固醇晶体提供了一种潜在的策略,并可进一步用于其他胆固醇过度积累的疾病。